首页 | 本学科首页   官方微博 | 高级检索  
     检索      

硫酸镁联合缬沙坦与拉贝洛尔对妊娠高血压患者白血病抑制因子、同型半胱氨酸水平的影响
引用本文:丁春云,李鸿.硫酸镁联合缬沙坦与拉贝洛尔对妊娠高血压患者白血病抑制因子、同型半胱氨酸水平的影响[J].中国药物经济学,2020(3):123-125.
作者姓名:丁春云  李鸿
作者单位:成武县人民医院产一科
摘    要:目的探讨硫酸镁联合缬沙坦、拉贝洛尔对妊娠高血压患者白血病抑制因子(LIF)、同型半胱氨酸(Hcy)水平的影响。方法选取2016年4月至2017年5月成武县人民医院收治的82例妊娠高血压患者作为研究对象,随机分为对照组与观察组,各41例。对照组应用硫酸镁治疗,观察组在对照组基础上联合缬沙坦及拉贝洛尔治疗,比较两组的治疗结果。结果两组治疗前舒张压、收缩压、24h尿蛋白定量水平比较,差异无统计学意义(P>0.05);治疗后,观察组张压、收缩压、24 h尿蛋白定量水平低于对照组,差异有统计学意义(P<0.05);两组治疗前LIF、Hcy水平比较,差异无统计学意义(P>0.05);观察组治疗后LIF水平高于对照组,Hcy水平低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为12.19%,与对照组7.32%比较,差异无统计学意义(P>0.05)。结论硫酸镁联合缬沙坦、拉贝洛尔治疗妊娠高血压安全有效,可改善患者血压水平,调节血清LIF、Hcy水平,且不会增加不良反应。

关 键 词:硫酸镁  缬沙坦  拉贝洛尔  妊娠高血压

Effects of Magnesium Sulfate Combined with Valsartan and Labetalol on Leukemia Inhibitory Factor and Homocysteine Levels in Patients with Gestational Hypertension
DING Chun-Yun,LI Hong.Effects of Magnesium Sulfate Combined with Valsartan and Labetalol on Leukemia Inhibitory Factor and Homocysteine Levels in Patients with Gestational Hypertension[J].China Journal of Pharmaceutical Economics,2020(3):123-125.
Authors:DING Chun-Yun  LI Hong
Institution:(No.l Department of Obstetrics,Chengwu County People's Hospital,Heze 274200,China)
Abstract:Objective To explore the effects of Magnesium sulfate combined with valsartan and labetalol on leukemia inhibitory factor(LIF)and Homocysteine(Hcy)levels in the treatment of patients with gestational hypertension.Methods A total of 82 patients with gestational hypertension in Chengwu County People’s Hospital from April 2016 to may 2017 were selected as the research objects and were randomly divided into an observation group(n=41)and a control group(n=41).The control group was treated with magnesium sulfate.On this basis,the observation group was treated with valsartan and labetalol.The results of the 2 groups were compared.Results There was no significant difference in diastolic blood pressure,systolic blood pressure and 24 h urine protein quantitative level between the 2 groups before treatment(P>0.05);After treatment,the above levels in the observation group was lower than those in the control group and there was no significant difference(P<0.05);Before treatment,the level of LIF in the observation group was higher than that in the control group,and the level of Hcy was lower than that in the control group.The difference was statistically significant(P<0.05);The incidence of adverse reactions in the observation group was 12.19%,which was not significantly different from that in the control group 7.32%(P>0.05).Conclusion Magnesium sulfate combined with valsartan and labetalol is safe and effective in the treatment of pregnancy hypertension.It can improve the blood pressure level of patients,regulate the level of LIF and Hcy in serum,with high sategy and will not increase too many adverse reactions.
Keywords:Magnesium sulfate  Valsartan  Labetalol  Pregnancy hypertension
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号